# US 2023/0058666 A1 · Initiating neurotoxin treatments

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0058666 A1
- Document ID: US20230058666A1
- Status: Published application
- Kind: A1
- Application number: 17/659,873
- Filed: 2022-04-20
- Published: 2023-02-23
- Earliest claimed: 2017-04-21
- Assignees: Bonti, Inc.
- Applicants: Bonti, Inc.
- Inventors: Fauad Hasan; Michael Jarpe
- Web page: https://patentgrep.com/patent/US20230058666A1

## CPC

- A61K 38/4893: {Botulinum neurotoxin (3.4.24.69)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 25/00: Drugs for disorders of the nervous system
- C12Y 304/24069: Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Disclosed herein are compositions and methods for use in initiating neurotoxin treatments.

## Claims

### Claim 1

A method for initiating a neurotoxin treatment in a neurotoxin-naïve patient, comprising administering to the patient a therapeutically effective amount of a fast-acting neurotoxin to a patient in an area where treatment is desired.

### Claim 2 (depends on 1)

The method of claim 1, wherein said fast-acting neurotoxin comprises botulinum neurotoxin serotype E.

### Claim 3 (depends on 2)

The method of claim 2, wherein said therapeutically effective amount comprises an amount of between about 0.2 and 20 ng.

### Claim 4 (depends on 3)

The method of claim 3, wherein said therapeutically effective amount comprises an amount of between about 2 and 10 ng.

### Claim 5 (depends on 3)

The method of claim 3, wherein said administration comprises an injection.

### Claim 6 (depends on 5)

The method of claim 5, wherein said method further comprises administration of an intermediate-acting neurotoxin to the patient.

### Claim 7 (depends on 5)

The method of claim 5, wherein said method further comprises administration of a long-acting neurotoxin to the patient.

### Claim 8 (depends on 5)

The method of claim 5, wherein said administration comprises an injection to the glabellar complex.

### Claim 9 (depends on 8)

The method of claim 8, wherein said glabellar complex comprises at least one of the corrugator supercilli and the procerus; the obicularis oculi; the superolateral fibers of the obicularis oculi; the frontalis; the nasalis; the levator labii superioris aleque nasi; the obicularis oris; the masseter; the depressor anguli oris; and the platysma.

### Claim 10 (depends on 1)

The method of claim 1, wherein said patient is a clostridial neurotoxin-naïve patient.

### Claim 11 (depends on 11)

The method of claim 11, wherein said patient is a botulinum type E neurotoxin-naïve patient.
